Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen

Authors:

Abstract
No abstract available
Funding Information
  • Allergan
  • National Institute of Allergy and Infectious Diseases
  • Merck (T32 AI007044)

This publication has 30 references indexed in Scilit: